European Parliament Passes SPC Manufacturing Waiver

A waiver to allow manufacturing of generics and biosimilars during the term of supplementary protection certificates is on the verge of being realized after the European Parliament approved the Regulation by a large majority.

Brussels
The Parliament Passed The SPC Manufacturing Waiver By A Wide Majority • Source: Shutterstock

Europe’s off-patent industry has welcomed the European Parliament’s decision to approve by a significant majority a Regulation setting out a waiver that will allow firms to manufacture generics and biosimilars during the term of supplementary protection certificates (SPCs).

“The European Parliament today voted overwhelmingly with 572 members of parliament in favour to adopt the SPC manufacturing waiver,” celebrated...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Legal & IP

  • ADHD

    This is regarding ADHD.

  • GB-Leadership-Free: Article with 150 words (Time to read is < 1 min)

     
    • By 

    In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.

  • MPP Finds Three More Partners On Key Hepatitis C Treatment

     
    • By 

    The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

  • Troubled Teligent Enters Bankruptcy Proceedings As CEO Resigns

     
    • By 

    Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.

More from Generics Bulletin